Wellcome Trust Clinical PhD Programme at the University of Oxford: gene therapy for multiple endocrine neoplasia type 1 (MEN1). (360G-Wellcome-087332_Z_08_Z)

£290,213

Multiple Endocrine Neoplasia type 1 (MEN1) is an autosomal dominant disorder characterised by the combined occurrence of parathyroid, pancreatic islet, anterior pituitary and adrenocortical tumours for which effective treatments are not available. The MEN1 gene is located on chromosome 11q13 and encodes a 610 amino acid protein, MENIN. MENIN has functions in transcriptional regulation and genome stability. Dr. Wood's group has successfully used adenoviral vectors for gene therapy and Professor Thakker has generated a MEN1 knockout mouse model. Heterozygous mice develop the expected endocrine tumours. The MEN1 gene has many similarities to the tumour suppressor functions of the retinoblastoma (Rb) gene. The main purpose of the proposed research is to suppressor functions of the retinoblastoma (Rb) gene. The main purpose of the proposed research is to suppress the tumourigenicity of MEN1 associated tumours by effective and sustained delivery of the wild type (WT) MEN1 gene using a gene therapy vector.

Where is this data from?

This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.

Grant Details

Amount Awarded 290213
Applicant Surname Javid
Approval Committee Neurosciences And Mental Health
Award Date 2008-09-16T00:00:00+00:00
Financial Year 2007/08
Grant Programme: Title PhD Training Fellowship for Clinicians
Internal ID 087332/Z/08/Z
Lead Applicant Miss Mahsa Javid
Partnership Value 290213
Planned Dates: End Date 2011-09-30T00:00:00+00:00
Planned Dates: Start Date 2008-10-01T00:00:00+00:00
Recipient Org: Country United Kingdom
Region South East
Sponsor(s) Prof Rajesh Thakker